Research Progress of the Treatment of PD-1 Immune CheckpointInhibitors in Oral Squamous Cell Carcinoma

Targeted immune checkpoint-based immunotherapy has achieved remarkable success in the treatment of malignant tumors.Immune checkpoint inhibitor-programmed cell death protein 1(PD-1)antibody opens a new era of immunotherapy for platinum-refractory recurrent/metastatic oral squamous cell carcinoma(OSCC).The overall survival of patients treated with immunological checkpoint inhibitors was significantly prolonged,and the overall incidence of grade 3-4 drug-related adverse events(AEs)occurred was lower;however,there are still some challenges to the PD-1’s application in OSCC clinic treatment.This article is just to briefly highlight the development of such application to date.